4:18 PM ET
8-K
Financial Results
Rezolute Financial Results
Rezolute, Inc. reported financial results for its first fiscal quarter ended September 30, 2026, ending the period with $90.0 million in cash and investments. The company provided clinical updates on its ersodetug program, noting that enrollment is complete for the Phase 3 upLIFT study in tumor HI with topline results expected in December 2026, and plans to submit a BLA for one or both HI indications in 2027.
- Term
- Q1 2027